Details of the Drug

General Information of Drug (ID: DMVRLT7)

Drug Name

Fludarabine

Synonyms

FaraA; Fludarabina; Fludarabinum; Fluradosa; Fludarabina [Spanish]; Fludarabine [INN]; Fludarabinum [Latin]; SQ Fludarabine; Fludara, Fludarabine; Fludarabine (INN); Fluradosa (TN); F-Ara-A; (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 2-F-ara-A; 2-Fluoro Ara-A; 2-Fluoro-9-beta-D-arabinofuranosyladenine; 9-beta-D-Arabinofuranosyl-2-fluoroadenine; 9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine; 9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro-(9CI)

Indication

Disease Entry	ICD 11	Status	REF
Haematological malignancy	2B33.Y	Approved	[1], [2]

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

285.23

Topological Polar Surface Area (xlogp)

-0.6

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability: The bioavailability of drug is 55% [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 20 hours [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 2.6598 micromolar/kg/day [6]
Water Solubility: The ability of drug to dissolve in water is measured as 3.53 mg/mL [3]

Chemical Identifiers

Formula: C10H12FN5O4
IUPAC Name: (2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
Canonical SMILES: C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)F)N
InChI: InChI=1S/C10H12FN5O4/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(19)5(18)3(1-17)20-9/h2-3,5-6,9,17-19H,1H2,(H2,12,14,15)/t3-,5-,6+,9-/m1/s1
InChIKey: HBUBKKRHXORPQB-FJFJXFQQSA-N

Cross-matching ID

PubChem CID: 657237
ChEBI ID: CHEBI:94701
CAS Number: 21679-14-1
DrugBank ID: DB01073
TTD ID: D0F2XQ
VARIDT ID: DR00434

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenosine deaminase (ADA)	TTLP57V	ADA_HUMAN	Inhibitor	[7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Fludarabine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Fludarabine and Roflumilast.	Asthma [CA23]	[15]
Ofloxacin	DM0VQN3	Minor	Decreased absorption of Fludarabine due to intestinal mucosa variation caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[16]
Sparfloxacin	DMB4HCT	Minor	Decreased absorption of Fludarabine due to intestinal mucosa variation caused by Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[16]
Gemifloxacin	DMHT34O	Minor	Decreased absorption of Fludarabine due to intestinal mucosa variation caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[16]
ABT-492	DMJFD2I	Minor	Decreased absorption of Fludarabine due to intestinal mucosa variation caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[16]
Levofloxacin	DMS60RB	Minor	Decreased absorption of Fludarabine due to intestinal mucosa variation caused by Levofloxacin.	Bacterial infection [1A00-1C4Z]	[16]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of peripheral neuropathy by the combination of Fludarabine and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[17]
Teriflunomide	DMQ2FKJ	Major	Additive myelosuppressive effects by the combination of Fludarabine and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[18]
Denosumab	DMNI0KO	Moderate	Additive myelosuppressive effects by the combination of Fludarabine and Denosumab.	Low bone mass disorder [FB83]	[19]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Fludarabine and Tecfidera.	Multiple sclerosis [8A40]	[20]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Fludarabine and Siponimod.	Multiple sclerosis [8A40]	[21]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Fludarabine and Fingolimod.	Multiple sclerosis [8A40]	[22]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Fludarabine and Ocrelizumab.	Multiple sclerosis [8A40]	[23]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Fludarabine and Ozanimod.	Multiple sclerosis [8A40]	[15]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive myelosuppressive effects by the combination of Fludarabine and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[24]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Fludarabine and Canakinumab.	Rheumatoid arthritis [FA20]	[25]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Fludarabine and Rilonacept.	Rheumatoid arthritis [FA20]	[25]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Fludarabine and Golimumab.	Rheumatoid arthritis [FA20]	[26]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Fludarabine when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[27]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Fludarabine and Valganciclovir.	Virus infection [1A24-1D9Z]	[21]
-----------


⏷ Show the Full List of 20 DDI Information of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4802).
2	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3	BDDCS applied to over 900 drugs
4	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Purine nucleoside analogs in indolent non-Hodgkin's lymphoma. Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):13-5.
8	Cladribine: from the bench to the bedside--focus on hairy cell leukemia. Expert Rev Anticancer Ther. 2004 Oct;4(5):745-57.
9	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
10	Clinical pipeline report, company report or official report of GlaxoSmithKline.
11	Clinical pipeline report, company report or official report of Orchard Therapeutics.
12	Tight-binding inhibitors--IV. Inhibition of adenosine deaminases by various inhibitors. Biochem Pharmacol. 1977 Mar 1;26(5):359-67.
13	Adenosine deaminase inhibitors: synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2'S-hydroxy-3'R... J Med Chem. 2000 Nov 30;43(24):4694-700.
14	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
15	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
16	Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
17	Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
18	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
19	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
20	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
21	Cerner Multum, Inc. "Australian Product Information.".
22	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
23	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
24	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
25	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
26	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
27	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]